NeuShen Therapeutics completes Series A+ financing raising tens of millions USD to accelerate CNS innovation pipeline development

NeuShen Therapeutics, an innovative biopharmaceutical company focused on the central nervous system (CNS) field, announced the successful completion of a Series A+ financing round totaling tens of millions of US dollars. This round was led by Lilly Asia Ventures (LAV), a globally leading life sciences investment firm, with participation from Pivotal bioVenture Partners. Existing shareholders, including Shanghai Healthcare Capital, Lapam Capital, and TTM Capital, continued their support in this round. The raised funds will primarily be used to advance preclinical studies and clinical trials for multiple globally competitive CNS innovative drug pipelines at NeuShen Therapeutics, addressing significant unmet clinical needs worldwide.

Dr. Huaqiong Shen, Founder and Chief Executive Officer of NeuShen Therapeutics, stated, "We are deeply grateful to Lilly Asia Ventures and all our new and existing investors for their trust and support in the NeuShen team. The success of this financing round strongly validates our strategy of focusing on major CNS diseases and leveraging cutting-edge science for differentiated drug development. The CNS field presents both challenges and opportunities. We are committed to accelerating the development of our existing pipelines and advancing breakthrough-potential drug candidates into clinical stages, aiming to provide revolutionary treatment options for patients globally."